

Shi-Xue Dai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/683307/publications.pdf>

Version: 2024-02-01

15
papers

628
citations

1039880

9
h-index

996849

15
g-index

16
all docs

16
docs citations

16
times ranked

1153
citing authors

#	ARTICLE	IF	CITATIONS
1	New Insights and Advances in Pathogenesis and Treatment of Very Early Onset Inflammatory Bowel Disease. <i>Frontiers in Pediatrics</i> , 2022, 10, 714054.	0.9	5
2	Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an <i>in silico</i> strategy towards precision oncology. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	126
3	Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. <i>Travel Medicine and Infectious Disease</i> , 2020, 35, 101647.	1.5	227
4	Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1886-1895.	0.9	26
5	Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 507-516.	1.4	32
6	Artificial liver research output and citations from 2004 to 2017: a bibliometric analysis. <i>PeerJ</i> , 2019, 6, e6178.	0.9	7
7	Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. <i>Clinical Nutrition</i> , 2018, 37, 123-129.	2.3	75
8	Comment on "Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations". <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1259-1259.	0.6	8
9	Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Anti-tumour Necrosis Factor Alpha Agents: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1042-1052.	0.6	7
10	Disequilibrium in the CD8+CD28+/CD8+CD28 [~] T Lymphocyte Balance Is Related to Prognosis in Rats with Trinitrobenzenesulfonic Acid-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 639-651.	1.1	4
11	CD8 + CD28 + /CD8 + CD28 [~] T cell equilibrium can predict the active stage for patients with inflammatory bowel disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, 693-702.	0.7	11
12	Decreased CD8+CD28+/CD8+CD28 [~] T cell ratio can sensitively predict poor outcome for patients with complicated Crohn disease. <i>Medicine (United States)</i> , 2017, 96, e7247.	0.4	7
13	Tumor Necrosis Factor Alpha Blocking Agents as Treatment for Ulcerative Colitis Intolerant or Refractory to Conventional Medical Therapy: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e86692.	1.1	41
14	Balance of CD8+CD28+/CD8+CD28 [~] T Lymphocytes Is Vital for Patients with Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 88-96.	1.1	13
15	Baicalin Down-regulates the Expression of Macrophage Migration Inhibitory Factor (MIF) Effectively for Rats with Ulcerative Colitis. <i>Phytotherapy Research</i> , 2012, 26, 498-504.	2.8	39